Developing better treatments for patients in need
At MyMD, we’re partnering with internationally renowned scientists and academics to validate the promise of our drug candidates as anti-inflammatory and anti-ageing technologies that treat the causes of disease and decline rather than simply focusing on the symptoms. We are working to rapidly advance MYMD-1® and Supera-CBD in clinical trials while identifying and validating additional novel targets.
We recently partnered with The Bascom Palmer Eye Institute, the number one eye hospital in the US, to preclinically evaluate MYMD-1® as a potentially safe, effective, and easily administrable treatment for traumatic optic neuropathy (TON). In addition, we have had collaborations with highly regarded institutions including the Johns Hopkins University School of Medicine which recently resulted in publication of a preclinical study in Journal of Gerontology: Biological Sciences.